OS6.2 Medulloblastoma recurrence: Improved survival with a metronomic and targeted antiangiogenesis therapy - experience in 
18 patients

INTRODUCTION: Patients with recurrent medulloblastoma have a poor prognosis with approximately 8% surviving more than 5 years irrespective of salvage therapy used. An evolving alternative approach to conventional chemotherapy is to target neovascularisation by interfering with tumor angiogenesis at...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Slavc, I., Peyrl, A., Azizi, A. A., Gojo, J., Chocholous, M., Czech, T., Dieckmann, K., Haberler, C.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
OS6 Pediatric Brain Tumors
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782543/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.044
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items